Bayer consolidation
Executive Summary
Bayer plans to cut pharmaceutical business operating costs by about $370 mil. in 18 months by eliminating 1,300 staff positions and closing West Haven, Conn. production facility, company says May 22. West Haven manufacturing will be transferred to plants in Europe and Shawnee, Kan. The latest layoffs bring the total number of job cuts announced since Bayer's Baycol withdrawal in August to 2,600 (1"The Pink Sheet" Oct. 8, 2001, In Brief)...
You may also be interested in...
Bayer Baycol-related layoffs
Bayer will cut pharmaceutical group by 1,250 employees following withdrawal of the cholesterol-reducing drug Baycol (cerivastatin), CFO Werner Wenning says Oct. 2. The cuts are on top of a previously announced global headcount reduction by 4,000 positions (not all of which are in pharma)
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.